Andrew Guggenhime Vaxcyte, Inc. (PCVX) insider trading activity

Andrew Guggenhime is PRESIDENT AND CFO of Vaxcyte, Inc.. Currently has a direct ownership of 96,720 shares of PCVX, which is worth approximately $7.36 Million. The most recent transaction as insider was on Jun 18, 2024, when has been sold 8,000 shares (Common Stock) at a price of $72.22 per share, resulting in proceeds of $577,760. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 96.7K

1.09% 3M change

17.95% 12M change

Total Value Held $7.36 Million

ANDREW GUGGENHIME Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jun 18 2024	SELL Open market or private sale	$577,760 $72.22 p/Share	8,000 Reduced 7.64%	96,720 Common Stock
Jun 18 2024	BUY Exercise of conversion of derivative security	$42,800 $5.35 p/Share	8,000 Added 7.1%	104,720 Common Stock
May 20 2024	SELL Open market or private sale	$599,440 $74.93 p/Share	8,000 Reduced 7.72%	95,679 Common Stock
May 20 2024	BUY Exercise of conversion of derivative security	$42,800 $5.35 p/Share	8,000 Added 7.16%	103,679 Common Stock
Apr 18 2024	SELL Open market or private sale	$492,560 $61.57 p/Share	8,000 Reduced 7.72%	95,679 Common Stock
Apr 18 2024	BUY Exercise of conversion of derivative security	$42,800 $5.35 p/Share	8,000 Added 7.16%	103,679 Common Stock
Mar 18 2024	SELL Open market or private sale	$554,560 $69.32 p/Share	8,000 Reduced 7.72%	95,679 Common Stock

Mar 18 2024	BUY Exercise of conversion of derivative security	$42,800 $5.35 p/Share	8,000 Added 7.16%	103,679 Common Stock
Mar 02 2024	SELL Payment of exercise price or tax liability	$271,532 $71.55 p/Share	3,795 Reduced 3.82%	95,679 Common Stock
Feb 29 2024	BUY Grant, award, or other acquisition	-	20,000 Added 16.74%	99,474 Common Stock
Feb 20 2024	SELL Open market or private sale	$600,160 $75.02 p/Share	8,000 Reduced 9.15%	79,474 Common Stock
Feb 20 2024	BUY Exercise of conversion of derivative security	$42,800 $5.35 p/Share	8,000 Added 8.38%	87,474 Common Stock
Jan 18 2024	SELL Open market or private sale	$493,360 $61.67 p/Share	8,000 Reduced 9.15%	79,474 Common Stock
Jan 18 2024	BUY Exercise of conversion of derivative security	$42,800 $5.35 p/Share	8,000 Added 8.38%	87,474 Common Stock
Dec 18 2023	SELL Open market or private sale	$483,840 $60.48 p/Share	8,000 Reduced 9.15%	79,474 Common Stock
Dec 18 2023	BUY Exercise of conversion of derivative security	$42,800 $5.35 p/Share	8,000 Added 8.38%	87,474 Common Stock
Dec 14 2023	SELL Open market or private sale	$843,080 $60.22 p/Share	14,000 Reduced 14.98%	79,474 Common Stock
Dec 14 2023	BUY Exercise of conversion of derivative security	$74,900 $5.35 p/Share	14,000 Added 13.03%	93,474 Common Stock
Nov 20 2023	SELL Open market or private sale	$412,320 $51.54 p/Share	8,000 Reduced 9.15%	79,474 Common Stock
Nov 20 2023	BUY Exercise of conversion of derivative security	$42,800 $5.35 p/Share	8,000 Added 8.38%	87,474 Common Stock
Oct 18 2023	SELL Open market or private sale	$368,800 $46.1 p/Share	8,000 Reduced 9.15%	79,474 Common Stock
Oct 18 2023	BUY Exercise of conversion of derivative security	$42,800 $5.35 p/Share	8,000 Added 8.38%	87,474 Common Stock
Sep 05 2023	SELL Payment of exercise price or tax liability	$181,968 $51.0 p/Share	3,568 Reduced 4.3%	79,474 Common Stock
Mar 02 2023	SELL Payment of exercise price or tax liability	$71,653 $41.49 p/Share	1,727 Reduced 2.06%	82,002 Common Stock
Mar 01 2023	BUY Grant, award, or other acquisition	-	22,500 Added 21.18%	83,729 Common Stock

Also insider at

MTCR

Metacrine, Inc. Healthcare

Director

CRBU

Caribou Biosciences, Inc. Healthcare

Director